The WACC of Bukwang Pharm Co Ltd (003000.KS) is 10.4%.
| Range | Selected | |
| Cost of equity | 7.70% - 10.20% | 8.95% |
| Tax rate | 25.00% - 25.00% | 25.00% |
| Cost of debt | 7.00% - 34.50% | 20.75% |
| WACC | 7.1% - 13.8% | 10.4% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.79 | 0.89 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 7.70% | 10.20% |
| Tax rate | 25.00% | 25.00% |
| Debt/Equity ratio | 0.3 | 0.3 |
| Cost of debt | 7.00% | 34.50% |
| After-tax WACC | 7.1% | 13.8% |
| Selected WACC | 10.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 003000.KS:
cost_of_equity (8.95%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.79) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.